Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion
Background and Purpose Carotid artery stenosis or occlusion (CASO) is a causative disease of vascular cognitive impairment (VCI) attributed to cerebral hypoperfusion, even without the development of symptomatic ischemic stroke. Preclinically, resveratrol has been demonstrated to play an important ro...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Stroke Society
2024-01-01
|
| Series: | Journal of Stroke |
| Subjects: | |
| Online Access: | http://www.j-stroke.org/upload/pdf/jos-2023-02733.pdf |
| _version_ | 1797321036119670784 |
|---|---|
| author | Yorito Hattori Yoshinori Kakino Yuji Hattori Mari Iwashita Hitoshi Uchiyama Kotaro Noda Takeshi Yoshimoto Hidehiro Iida Masafumi Ihara |
| author_facet | Yorito Hattori Yoshinori Kakino Yuji Hattori Mari Iwashita Hitoshi Uchiyama Kotaro Noda Takeshi Yoshimoto Hidehiro Iida Masafumi Ihara |
| author_sort | Yorito Hattori |
| collection | DOAJ |
| description | Background and Purpose Carotid artery stenosis or occlusion (CASO) is a causative disease of vascular cognitive impairment (VCI) attributed to cerebral hypoperfusion, even without the development of symptomatic ischemic stroke. Preclinically, resveratrol has been demonstrated to play an important role in improving cognitive function in rodent CASO models. This study investigated the association between long-term resveratrol intake and improvements in cognitive and cerebral hemodynamic impairments in patients with CASO. Methods A retrospective cohort study was conducted on patients with asymptomatic carotid artery stenosis of ≥50% or occlusion who underwent 15O-gas positron emission tomography (15O-gas PET) and neuropsychological tests such as Montreal Cognitive Assessment (MoCA) and Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog) twice between July 2020 and March 2022 allowing >125-day interval. Patients were administered 30 mg/day resveratrol after the first 15O-gas PET and neuropsychological tests were compared with those who were not. Results A total of 79 patients were enrolled in this study; 36 received resveratrol and 43 did not. Over a mean follow-up of 221.2 and 244.8 days, long-term resveratrol treatment significantly improved visuospatial/executive function (P=0.020) in MoCA, and memory domain (P=0.007) and total score (P=0.019) in ADAS-Cog. Cerebral blood flow demonstrated improvement in the right frontal lobe (P=0.027), left lenticular nucleus (P=0.009), right thalamus (P=0.035), and left thalamus (P=0.010) on 15O-gas PET. No adverse events were reported. Conclusion Long-term daily intake of oral resveratrol may prevent or treat VCI by improving the cerebral blood flow in asymptomatic patients with CASO. |
| first_indexed | 2024-03-08T04:51:42Z |
| format | Article |
| id | doaj.art-78a8b3228457484e8379d7efc93848f6 |
| institution | Directory Open Access Journal |
| issn | 2287-6391 2287-6405 |
| language | English |
| last_indexed | 2024-03-08T04:51:42Z |
| publishDate | 2024-01-01 |
| publisher | Korean Stroke Society |
| record_format | Article |
| series | Journal of Stroke |
| spelling | doaj.art-78a8b3228457484e8379d7efc93848f62024-02-08T04:10:26ZengKorean Stroke SocietyJournal of Stroke2287-63912287-64052024-01-01261647410.5853/jos.2023.02733517Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/OcclusionYorito Hattori0Yoshinori Kakino1Yuji Hattori2Mari Iwashita3Hitoshi Uchiyama4Kotaro Noda5Takeshi Yoshimoto6Hidehiro Iida7Masafumi Ihara8 Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan Department of Pharmacology, National Cerebral and Cardiovascular Center, Suita, Japan R&D Division, Towa Pharmaceutical Co., Ltd., Kadoma, Japan R&D Division, Towa Pharmaceutical Co., Ltd., Kadoma, Japan Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan Turku PET Centre, University of Turku, Turku, Finland Department of Neurology, National Cerebral and Cardiovascular Center, Suita, JapanBackground and Purpose Carotid artery stenosis or occlusion (CASO) is a causative disease of vascular cognitive impairment (VCI) attributed to cerebral hypoperfusion, even without the development of symptomatic ischemic stroke. Preclinically, resveratrol has been demonstrated to play an important role in improving cognitive function in rodent CASO models. This study investigated the association between long-term resveratrol intake and improvements in cognitive and cerebral hemodynamic impairments in patients with CASO. Methods A retrospective cohort study was conducted on patients with asymptomatic carotid artery stenosis of ≥50% or occlusion who underwent 15O-gas positron emission tomography (15O-gas PET) and neuropsychological tests such as Montreal Cognitive Assessment (MoCA) and Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog) twice between July 2020 and March 2022 allowing >125-day interval. Patients were administered 30 mg/day resveratrol after the first 15O-gas PET and neuropsychological tests were compared with those who were not. Results A total of 79 patients were enrolled in this study; 36 received resveratrol and 43 did not. Over a mean follow-up of 221.2 and 244.8 days, long-term resveratrol treatment significantly improved visuospatial/executive function (P=0.020) in MoCA, and memory domain (P=0.007) and total score (P=0.019) in ADAS-Cog. Cerebral blood flow demonstrated improvement in the right frontal lobe (P=0.027), left lenticular nucleus (P=0.009), right thalamus (P=0.035), and left thalamus (P=0.010) on 15O-gas PET. No adverse events were reported. Conclusion Long-term daily intake of oral resveratrol may prevent or treat VCI by improving the cerebral blood flow in asymptomatic patients with CASO.http://www.j-stroke.org/upload/pdf/jos-2023-02733.pdfresveratrolcarotid artery stenosiscarotid artery occlusiono-gas positron emission tomographycerebral blood flowvascular cognitive impairment |
| spellingShingle | Yorito Hattori Yoshinori Kakino Yuji Hattori Mari Iwashita Hitoshi Uchiyama Kotaro Noda Takeshi Yoshimoto Hidehiro Iida Masafumi Ihara Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion Journal of Stroke resveratrol carotid artery stenosis carotid artery occlusion o-gas positron emission tomography cerebral blood flow vascular cognitive impairment |
| title | Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion |
| title_full | Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion |
| title_fullStr | Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion |
| title_full_unstemmed | Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion |
| title_short | Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion |
| title_sort | long term resveratrol intake for cognitive and cerebral blood flow impairment in carotid artery stenosis occlusion |
| topic | resveratrol carotid artery stenosis carotid artery occlusion o-gas positron emission tomography cerebral blood flow vascular cognitive impairment |
| url | http://www.j-stroke.org/upload/pdf/jos-2023-02733.pdf |
| work_keys_str_mv | AT yoritohattori longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT yoshinorikakino longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT yujihattori longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT mariiwashita longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT hitoshiuchiyama longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT kotaronoda longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT takeshiyoshimoto longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT hidehiroiida longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion AT masafumiihara longtermresveratrolintakeforcognitiveandcerebralbloodflowimpairmentincarotidarterystenosisocclusion |